TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. TAO Synergies Inc. was formerly know Synaptogenix, Inc. as and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York. Show more

Location: 1185 Avenue of the Americas, New York, NY, 10036, United States | Website: https://www.synaptogen.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

8.401M

52 Wk Range

$1.84 - $6.19

Previous Close

$6.04

Open

$6.39

Volume

986,733

Day Range

$5.63 - $7.85

Enterprise Value

-5.153M

Cash

14.83M

Avg Qtr Burn

-1.263M

Insider Ownership

1.90%

Institutional Own.

3.76%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bryostatin-1 Details Alzheimer's disease	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bryostatin-1 Details Fragile X syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.